Business Description
Onconetix Inc
NAICS : 541713
SIC : 2834
ISIN : US68237Q2030
Total Employee Number:
2Description
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 12.81 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -13.97 | |||||
Beneish M-Score | 0.55 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 86.2 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.12 | |||||
9-Day RSI | 30.77 | |||||
14-Day RSI | 27.2 | |||||
3-1 Month Momentum % | -96.09 | |||||
6-1 Month Momentum % | -98.24 | |||||
12-1 Month Momentum % | -99.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.41 | |||||
Quick Ratio | 1.37 | |||||
Cash Ratio | 1.21 | |||||
Days Inventory | 366.96 | |||||
Days Sales Outstanding | 36.95 | |||||
Days Payable | 5026.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | 202.33 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 79.73 | |||||
Operating Margin % | -922.86 | |||||
Net Margin % | -1319.86 | |||||
EBITDA Margin % | -1245.58 | |||||
FCF Margin % | -1333.33 | |||||
OCF Margin % | -1333.33 | |||||
ROE % | -117.4 | |||||
ROA % | -49.83 | |||||
ROIC % | -27.59 | |||||
3-Year ROIIC % | 28.84 | |||||
ROC (Joel Greenblatt) % | -10971.29 | |||||
ROCE % | -108.94 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.03 | |||||
PB Ratio | 0.02 | |||||
Price-to-Tangible-Book | 0.17 | |||||
EV-to-EBIT | -0.02 | |||||
EV-to-EBITDA | -0.02 | |||||
EV-to-Revenue | 0.24 | |||||
EV-to-FCF | -0.02 | |||||
| Price-to-Net-Current-Asset-Value | 0.22 | |||||
| Price-to-Net-Cash | 0.43 | |||||
Earnings Yield (Greenblatt) % | -5000 | |||||
FCF Yield % | -271.84 |
GF Valueâ„¢
Onconetix Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Onconetix Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-04 11:00 | In 159 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 137 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 46 days | ||
| 0.1:1 Stock Split | 2026-05-21 | 1.10 (-1.79%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 4.08 (+1.95%) | ||
| 0.2:1 Stock Split | 2026-03-25 | 28.68 (-5.05%) | ||
| Annual report for 2025 | 2026-03-13 | 28.64 (-7.63%) | ||
| General meeting for 2025 | 2025-12-05 11:00 | 147.50 (-2.32%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 137.50 (-0.27%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 155.00 (+6.16%) |
Show
Entries
Guru Commentaries on NAS:ONCO
No articles.
Press Release
Articles on Onconetix Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers